Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
作者
M. Piccart,K. Bertelsen,Gavin Stuart,J. Cassidy,C. Mangioni,Erik B. Simonsen,K. James,Samantha L. Kaye,Ignace Vergote,R. Blom,Robert Grimshaw,R. Atkinson,K. Swenerton,Claes G. Tropé,Marco Nardi,J. Kærn,Salvatore Tumolo,P.J. Timmers,J.A. Roy,F. Lhoas